Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Bayer faces Swiss criminal probe over cerivastatin

2002; BMJ; Volume: 324; Issue: 7330 Linguagem: Inglês

10.1136/bmj.324.7330.130b

ISSN

0959-8138

Autores

Fiona Fleck,

Tópico(s)

Pharmaceutical Economics and Policy

Resumo

Prosecutors in the Swiss canton of Ticino have opened a criminal inquiry into Bayer AG on suspicion of fraud and grievous bodily damage following the German pharmaceutical giant's controversial recall of its cholesterol drug cerivastatin sodium in August last year. Cantonal prosecutor Nicola Respini told the BMJ on Friday that he had opened the investigation on 4 December after a patient taking cerivastatin (marketed as Lipobay …

Referência(s)